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a  b  s  t  r  a  c  t
Despite  high  vaccination  coverage,  pertussis  is  still  a global  concern  in infant  morbidity  and  mortality,
and  improved  pertussis  vaccines  are  needed.  A live  attenuated  Bordetella  pertussis  strain,  named  BPZE1,
was  designed  as  an  intranasal  vaccine  candidate  and  has  recently  been  tested  in man  in  a  phase  I clinical
trial.  Here,  we  report  the evaluation  of the  B-cell  responses  after  vaccination  with  BPZE1.  Forty-eight
healthy  males  with  no  previous  pertussis-vaccination  were  randomized  into  one  of three  dose-escalating
groups  or into  a placebo  group.  Plasma  blast-  and  memory  B-cell  responses  were  evaluated  by  ELISpot
against  three  different  pertussis  antigens:  pertussis  toxin,  ﬁlamentous  haemagglutinin  and  pertactin.
Seven  out  of  the  36  subjects  who  had  received  the  vaccine  were  colonized  by  BPZE1,  and  signiﬁcant
increases  in  the  memory  B-cell  response  were  detected  against  all three  tested  antigens  in  the  culture-ive attenuated nasal vaccine
hase I clinical trial
ovel human vaccine
positive subjects  between  days  0 and  28  post-vaccination.  The  culture-positive  subjects  also  mounted
a signiﬁcant  increase  in  the  ﬁlamentous  haemagglutinin-speciﬁc  plasma  blast  response  between  days  7
and 14  post-vaccination.  No  response  could  be detected  in  the culture-negatives  or in the  placebo  group
post-vaccination.  These  data  show  that  BPZE1  is immunogenic  in  humans  and  is  therefore  a promising
candidate  for  a novel  pertussis  vaccine.  This  trial is  registered  at ClinicalTrials.gov  (NCT01188512).
© 2014  Published  by Elsevier  Ltd.  This is an  open  access  article  under  the  CC  BY-NC-ND  license. Introduction
Bordetella pertussis (B. pertussis) is the causative agent of whoop-
ng cough, a disease that despite high vaccination coverage still
emains a major concern in infant mortality and morbidity. The
ntroduction of pertussis vaccines greatly decreased the incidence
f pertussis disease and mortality [1]. There are two  types of avail-
ble pertussis vaccines, whole-cell (Pw) and acellular (Pa). The ﬁrst
ose of the vaccine is given at the age of 2–3 months [2–4]. Infants
Abbreviations: ASC, antibody secreting cells; FHA, ﬁlamentous hemagglutinin;
a, acellular pertussis vaccine; PRN, pertactin; PT, pertussis toxin; Pw,  whole cell
ertussis vaccine; TTd, tetanus toxoid.
∗ Corresponding author at: Folkhälsomyndigheten, SE-171 82 Solna, Sweden.
el.: +46 10 205 25 56.
E-mail address: maja.jahnmatz@folkhalsomyndigheten.se (M. Jahnmatz).
ttp://dx.doi.org/10.1016/j.vaccine.2014.04.048
264-410X/© 2014 Published by Elsevier Ltd. This is an open access article under the CC (http://creativecommons.org/licenses/by-nc-nd/3.0/).
below four months are thus not optimally protected and are at risk
for severe and fatal pertussis [5]. Improving the current immuniza-
tion scheme so that young infants are offered protection is therefore
important.
A natural pertussis infection induces a type I T-helper (Th1) cell
response, and clearing of the primary infection depends on inter-
feron gamma  (IFN-) production [6,7]. Mouse studies have shown
a protective role for B cells as well [8,9]. In children, Pw-vaccines
are reported to induce a Th1-type proﬁle like a natural infection,
whereas Pa-vaccinated children are seen to induce a more Th1/Th2-
mixed type of response [10,11]. Mielcarek et al. have developed a
live attenuated B. pertussis vaccine strain named BPZE1 [12] with
the long-term aim to administer it to infants at birth. This vaccine
strain is attenuated by genetic removal of the dermonecrotic toxin
and the tracheal cytotoxin as well as detoxiﬁcation of the pertussis
toxin (PT). These alterations have not affected the immunogenic
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table after both continuous in vitro and in vivo passages over at
east one year [13]. It can colonize the respiratory tract and induce
ong-lasting memory B-cell responses, as well as T-cell mediated
rotective immunity against challenge in mice [12,14,15].
A recent randomized, placebo-controlled, double-blind, dose-
scalating phase I clinical trial has shown that BPZE1 is safe in
umans, able to transiently colonize the human nasopharynx and
o induce antibody responses [16]. Here, we have evaluated B-cell
esponses after vaccination with BPZE1. Plasma blast- and memory
-cell responses were detected by ELISpot, and B-cell subsets were
dentiﬁed by ﬂow cytometry.
. Materials and methods
.1. Ethical conductance of the study
The study was conducted according to the protocol ICH Good
linical Practices standards, Declaration of Helsinki and applica-
le regulatory requirements as well as any related European and
wedish applicable laws and regulations. The trial was registered
t ClinicalTrials.gov (NCT01188512) and approved by the Swedish
edical Product Agency and the regional ethical review board in
tockholm. All volunteers signed an informed consent form after
eceiving oral and written information in Swedish.
.2. Vaccine strain BPZE1 and dose groups
The clinical BPZE1 lots were produced by Innogenetics (Ghent,
elgium) as a suspension in phosphate-buffered saline (PBS) con-
aining 5% saccharose. Three doses of BPZE1 were tested, 103 colony
orming units (cfu), 105 cfu and 107 cfu, as described earlier [16].
he placebo group received diluent only.
.3. Subjects
The forty-eight healthy males (born between 1979 and 1991)
ecruited to the BPZE1 phase I clinical trial [16] were included for
-cell response evaluation. No subjects had previously received
ny pertussis vaccination as they were born during a time period
ithout any national pertussis vaccination. Due to the circulation
f pertussis in the population no subject was considered naïve
eaning that all had pertussis-speciﬁc antibodies pre-vaccination.
ubjects with any additional pertussis vaccination or a clinical per-
ussis during the preceding 10 years were excluded. Subclinical
nfections were excluded by including only subject with serum
nti-PT Ig levels of ≤20 IU/ml. More inclusion- and exclusion crite-
ia as well as study protocol are published in detail elsewhere [16].
lood samples were collected from all subjects pre-vaccination
day 0) and at days 7, 14, 28 and month 5–6 post-vaccination.
.4. Colonization of BPZE1After vaccination, all subjects were tested for bacterial shed-
ing as described in [16]. Seven subjects were positive for BPZE1
olonization at different time points. The positive cultures were
able 1
umber of subjects included in the study as well as in the plasma blast and memory B-ce
Dose group All subjects Plasma blast ELISpo
Culture negatives Culture positives Total Culture negatives 
Low 11 1 12 8 
Medium 11 1 12 6 
High  7 5 12 6 
Placebo 12 0 12 12 
a Only included in the culture positive analysis (Fig. 2B).32 (2014) 3350–3356 3351
sampled between day 4 and day 28, and bacterial shedding was
generally found around day 11 post-vaccination. No shedding was
detected after day 28 post-vaccination.
2.5. Antigens
PT (lot 042) and ﬁlamentous hemagglutinin [FHA] (lot 039) were
obtained from Kaketsuken, Japan. Pertactin [PRN] (lot 180805 RS)
was kindly provided by Dr. Buisman at RIVM, the Netherlands.
Tetanus Toxoid (TTd), lot 59-5, was  obtained from SSI, Denmark.
2.6. Puriﬁcation, cryopreservation and thawing of PBMC
Peripheral blood mononuclear cells (PBMC) were puriﬁed from
whole blood collected in BD Vacutainer® CPT tubes with sodium
heparin (Becton Dickinson, Franklin Lakes, NJ, USA) and separated
according to the manufacturer’s instruction. Cryopreservation and
thawing were performed as previously described [17] but using
freezing medium with 90% Fetal Calf Serum (Gibco Invitrogen, Pais-
ley, UK) and 10% Dimethyl Sulphoxide (DMSO) (Sigma–Aldrich, St.
Louis, MO,  USA).
2.7. B-cell ELISpot method
For the plasma blast analysis (days 7 and 14) fresh samples
were used and 38 subjects (of which 6 were culture positive)
were included. 10 subjects (low n = 3, medium n = 5 and high n = 2
[of which 1 was culture positive]) did not have available sam-
ples for days 7 and 14 post-vaccination. Frozen samples were
used for the memory B-cell analysis (days 0, 28 and 150–180)
and the analyses included all subjects in the medium and the
high dose groups (n = 32) as well as placebo subjects (n = 8). All 7
culture positive subjects were also included. The inclusion of sub-
jects (group wise and colonization status) is stated in Table 1. All
antigens included in the ELISpot-analysis were used at a coating
concentration of 0.5 g/well. A subject was  considered a vaccine
responder to an antigen if ≥50 antigen-speciﬁc antibody secreting
cells (ASC)/106 PBMC were detected and at least a 100% increase in
spot number/106 PMBC at any following time point compared to
day 0. This method has previously been described ([18], for speciﬁc
details see supplementary method S1).
2.8. Flow cytometry
For ﬂow cytometry analyses isolated PBMCs were washed,
plated at 1–2 × 106 cells per sample and stained using direct
ﬂuorochrome-conjugated antibodies in different combinations:
PerCp-Cy5.5 anti-CD19 (clone HIB19), PE-Cy7 anti-CD10 (HI10a),
V450 anti-CD27 (MT271), PE anti-CD21 (B-ly4), FITC anti-IgG (G18-
145), PE anti-IgG (G18-145) and FITC anti-IgD (IA6-2) all from
BD biosciences. APC anti-FCRL4 (413D12) was from BioLegend.
LIVE/DEAD Fixable Near-IR kit (Invitrogen) was used to exclude
the dead cells from analyses. Cells were washed three times before
being ﬁxed in 1% formaldehyde. All antibodies were used in the
concentrations determined after titration experiments. Matched
ll ELISpot analysis.
t Memory B-cell ELISpot
Culture positives Total Culture negatives Culture positives Total
1 9 0 (1a) (1a)
1 7 11 1 12
4 10 7 5 12
0 12 8 0 8
3352 M. Jahnmatz et al. / Vaccine 32 (2014) 3350–3356
Fig. 1. Plasma blast responses against BPZE1. (A) 38 subjects were included in the plasma blast analysis (low n = 9, medium n = 7, high n = 10, placebo n = 12). No vaccine-























oulture  negatives. A signiﬁcant increase could be detected against FHA (p = 0.0355
gainst the antigen. Two  of these subjects were also responding in PRN. No vaccine-r
igniﬁcance are marked in the ﬁgure. PT: pertussis toxin, FHA: ﬁlamentous hemagg
sotype controls were used to set up the gates. Fluorescence inten-
ities were measured with Cyan ADP (Beckman Coulter) and data
as analyzed using FlowJo, version 9.4.11 (Tree star). All samples
sed had previously been frozen.
The peripheral whole B-cell population was gated
ut as CD19+ cells after exclusion of dead cells. Whole
 cells were further subdivided into various B-cell sub-
ets using multi-color ﬂow cytometry panels. Immature
ransitional CD19+CD10+, Naive CD19+CD10−CD21+CD27−,
ctivated Memory CD19+CD10−CD21−CD27+, Resting
emory CD19+CD10−CD21+CD27+, Tissue Like Mem-
ry CD19+CD10−CD21−CD27−B cells, switched memory
 cells CD19+CD27+IgD−, Un-switched Memory B cells
D19+CD27+IgD+, Naive CD19+CD27−IgD+ and double nega-
ive B cells CD19+CD27−IgD−. The expression of IgG and FCRL4
as studied on all B-cell subsets.
.9. Statistics
All data were considered non-parametric, and p-values <0.05
ere considered statistically signiﬁcant. Comparisons between two
ime points were done with Wilcoxon matched-pairs signed rank
est. Comparisons between two or more groups were done with
ne-way ANOVA, Kruskal–Wallis test with Dunn post-test. Foreen days 7 and 14 in the culture positive subjects with three subjects responding
ders were detected in the culture negative subjects. Only results reaching statistical
n, PRN: pertactin, med: medium dose group.
comparison within one group at different time-points one-way
ANOVA with Friedman test and Dunn post-test were done. All sta-
tistical analyses were performed using GraphPad Prism (Graphpad
Software Inc., San Diego, USA).
3. Results
3.1. Plasma blast responses against BPZE1
When all 38 included subjects were considered, no signiﬁcant
increase in the antigen-speciﬁc plasma blast response was detected
between dose groups or between time points (Fig. 1a). However,
when the culture-positive subjects were analyzed, a signiﬁcant
increase (p = 0.0355) between days 7 and 14 could be detected
against FHA (Fig. 1b). Two of the FHA-responders also responded
to PRN. No vaccine-responders were detected in the culture nega-
tive group (Fig. 1b), or was  any response seen against the control
antigen TTd (data not shown).
3.2. Memory B-cell responses against BPZE1There was no signiﬁcant increase in antigen-speciﬁc responses
between time points or dose groups. However, in the high dose
group a response was seen at day 28 against all antigens, but did not
M. Jahnmatz et al. / Vaccine 32 (2014) 3350–3356 3353
Fig. 2. Memory B-cell responses against BPZE1. (A) All subjects in the medium and high dose group were included in the memory B-cell analysis (medium and high n = 12
each,  placebo n = 8). No signiﬁcant increase in antigen-speciﬁc memory B cells could be detected in the two groups between time points or compared to placebo. (B) The























jxcept  one who did not mount any PT-speciﬁc response. At day 150–180 this inc
aintained higher levels of antigen-speciﬁc memory B cells compared to day 0. No 
tatistical signiﬁcance are marked in the ﬁgure. PT: pertussis toxin, FHA: ﬁlamentou
each statistical signiﬁcance (Fig. 2a). The seven culture-positive
ubjects had signiﬁcant increases (p < 0.05) in antigen-speciﬁc
emory B cells between days 0 and 28 (Fig. 2b). All subjects
esponded against all antigens, except one who only had FHA-
nd PRN-speciﬁc responses. Between days 28 and 150–180 after
accination the numbers of antigen-speciﬁc memory B cells had
eclined. Some subjects were back to background levels, whereas
thers had maintained higher levels of antigen-speciﬁc mem-
ry B cells compared to day 0. One subject had maintained
he level of FHA-speciﬁc memory B cells between days 28 and
50–180. No vaccine-responders were seen in the culture-negative
roup (Fig. 2b) or against the control antigen TTd (data not
hown).
.3. Flow cytometric analysis of B-cell subsets
For an in-depth evaluation of the memory B-cell response two
anels were included in the ﬂow cytometric analysis. Panel I iden-
iﬁed different memory B-cell subpopulations (activated, resting
nd tissue-like) and panel II identiﬁed IgG-switched memory B
ells. Detection and analysis were performed for 12 subjects (4
ulture positives, 4 culture negatives and 4 placebos). Not all sub-
ects had samples available for all time points. No differenceshad declined, some subjects were back to background levels whereas others had
e-responders were detected in the culture negative subjects. Only results reaching
agglutinin, PRN: pertactin.
were found between the culture positives, culture negatives or
placebo when antibody isotype-switch was evaluated (IgD+/− and
IgG+/−), data not shown. However, there was an increase in the
culture-positive group at days 7 and 14 of the activated memory
B cells, as well as the tissue-like memory B cells (ﬁg. 3). This was
not seen in the naïve and resting memory B-cell subpopulations,
nor did the FcLR4 staining differ between the groups (data not
shown).
3.4. Comparison of serum IgG levels and B-cell responses
The number of responding subjects was insufﬁcient for a
thorough correlation analysis. Therefore, a more general compar-
ison of the B-cell responses detected was made. The serological
response (as detected by ELISA, reported in detail in Ref. [16]), the
plasma blast response and the memory B-cell response were com-
pared in all seven culture-positive subjects (Fig. 4). As expected,
the cellular response had declined in blood at day 150–180,
whereas the serological response was maintained. There were
minor exceptions where subjects differed between their cellular
and humoral responses, but in general the subjects responded sim-
ilarly in the antigen-speciﬁc responses detected by both ELISpot
and ELISA.
3354 M. Jahnmatz et al. / Vaccine 
Fig. 3. Flow cytometric analysis of B-cell subsets. 12 subjects were included in an
analysis of the BPZE1 vaccination inﬂuence on different B-cell subsets. Not all sub-
jects had available samples at all time points (days 0, 28 and 150–180 n = 12, day 7
n  = 10, day 14 n = 9). The culture positive subjects had an increase in the activated
memory B-cell response (CD19+CD10−CD21−CD27+) as well as the tissue-like mem-
























oot maintained at days 28 and 150–180 or seen in the culture negative subjects or
lacebo. No statistical signiﬁcance was reached in this evaluation. AM:  activated
emory, TLM: tissue-like memory.
. Discussion
The novel, live attenuated pertussis vaccine candidate, BPZE1,
as tested for the ﬁrst time in man  and showed to be safe and able
o induce serological responses [16]. In this study, we evaluated the
-cell responses evoked by BPZE1 during the same trial. In total 48
ubjects were recruited to the study. Out of the 36 subjects that
eceived the vaccine 7 were colonized by BPZE1 and mounted a
esponse against the vaccine-related antigens. Since it was  a ﬁrst-
n-man study, the dosages used in this study were based on studies
n mice [19]. An optimization of the doses may  perhaps lead to a
etter vaccine take.
The results obtained in this study are considered exploratory
ue to the novelty of the vaccine. The BPZE1-vaccine is not yet
ptimized and the results obtained from the clinical trial will serve
s guidance to continued development. Therefore, no comparison
ith other pertussis vaccines is made in this study. Also, the vast
ifferences in study populations, vaccination and administration
outes in this study compared to other published pertussis-vaccine
tudies impedes an accurate comparison.
The low detection of plasma blast responses suggests that an
ptimization regarding the sampling time points should be con-
idered in future studies. The BPZE1-vaccine immunogenicity is
ependent on bacterial colonization and it is likely that the col-
nization period delays the response compared to a parenterally32 (2014) 3350–3356
administrated vaccine [20]. Adjusting the sampling time point
could therefore enable a better detection of the BPZE1-induced
plasma blast response.
Nevertheless, all colonized subjects mounted strong pertussis-
speciﬁc memory B-cell responses between days 0 and 28 as
detected in blood. These responses had declined at month 5–6, but
despite suboptimal vaccine dosages, some subjects had maintained
higher memory B-cell responses compared to day 0. Using periph-
eral blood to analyze the long-term presence of memory B-cell
populations is not optimal, as memory B cells home to secondary
lymphoid organs and are only seen circulating in low frequencies
[21,22]. Studies in mice have shown that between days 28 and 40
following primary vaccination the frequencies of memory B cells
are similar in the spleen and the circulation [23]. This indicates
that the response detected in blood at day 28 in our study is a more
accurate estimation of the true number of pertussis-speciﬁc mem-
ory B cells than the response detected at month 5–6. Similar kinetics
with peak levels one month after vaccination, followed by declin-
ing levels of memory B cells in blood are reported in other studies,
both for an intranasal Norwalk-vaccine [24] as well as parenterally
administered diphtheria and pertussis vaccines [25–27].
We combined two  different ﬂow cytometry based phenotypi-
cal panels in order to analyze in depth the changes in frequency
and, to some extent, the phenotype of memory and naive B-cell
compartments after vaccination in the peripheral blood. Staining
for CD10, CD21 and CD27 on B cells enabled the identiﬁcation of
four different subsets (naïve, resting memory, activated memory
and tissue-like memory), whereas CD27 and IgD staining allowed
for the identiﬁcation of switched memory B cells. Each subset of
the B cells has been shown to have a different phenotype, indi-
cating a different function in the immune response. Their activity
following vaccination were therefore of interest to investigate. In
this limited analysis of the different memory B-cell subpopula-
tions we detected an increase in the activated memory B cells and
the tissue-like memory for a few culture positive subjects, indi-
cating active memory B-cell subsets following BPZE1 vaccination.
Tissue-like memory cells have previously only been identiﬁed as
an exhausted B cell subset in HIV-patients, and their role here is
unclear [28]. The antigen-speciﬁcity of the B cells was not inves-
tigated by ﬂow cytometry but as strong pertussis-responses were
detected in the other evaluations it is most likely induced by the
vaccine.
In the last years there has been a resurgence of pertussis cases
and infant deaths in countries with high vaccination coverage
[29–31], emphasizing the need for a different vaccine approach to
provide protection for the most susceptible infants. Studies have
shown that a primary dose of a Pw-vaccine reduces the risk of per-
tussis compared to a primary dose of a Pa-vaccine [30–32], and the
live attenuated BPZE1 vaccine may  be a promising priming candi-
date in that context. It has been shown to protect infant mice against
virulent B. pertussis challenge [12] and to provide long-term immu-
nity, substantially longer than Pa [33]. Complementing the current
pertussis immunization program with a birth-dose of BPZE1 in the
future could therefore offer a better protection for the vulnerable
infants. However, due to the immaturity of the infant immune sys-
tem, especially with respect to IFN- producing CD4+ T cells [34,35],
extensive studies of the BPZE1 safety and efﬁcacy in declining age
groups must be performed before a birth dose of BPZE1 is imple-
mented. In this regard it is, however, interesting to note that very
young infants are able to induce a strong B. pertussis-speciﬁc IFN-
producing CD4+ T cell response upon natural infection, in contrast
to vaccination with Pa [6].In conclusion, the novel attenuated pertussis vaccine strain
BPZE1 was  able to induce pertussis-speciﬁc B-cell responses in
colonized subjects. Nasopharyngeal colonization of BPZE1 was,
however, crucial for the induction of B-cells responses. With
M. Jahnmatz et al. / Vaccine 32 (2014) 3350–3356 3355
Fig. 4. Comparison of serum IgG levels and B-cell responses. The humoral and cellular response detected in the sevens subjects that had been colonized by BPZE1 were
compared. The numbers on the left hand side (110–346) are the subjects’ identiﬁcation number in the study. No major differences were seen in the responses and the subjects
responded against the same antigens in both the serological as well as the cell mediated response. The serological response was  maintained at day 150–180 whereas the
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ptimization, the BPZE1 is a promising candidate to supplement the
urrent pertussis vaccination schedule and thereby provide protec-
ion against pertussis disease.
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